Skip to main content

Article

What 2026 taught us about the future of pharmacy

Discover four pharmacy trends from 2026, including new business models, AI-powered services, menopause care and the evolving GLP-1 market.

November 20, 2026 | 4-minute read

Pharmacy services continued to evolve in 2026 as new ideas and enhanced capabilities emerged to help plan sponsors resist the ongoing trend of rising prescription drug costs. Here are four trends that helped define the past year.

A new model for pharmacy services

While the pharmacy care services business model pioneered by Optum Rx has been evolving for decades, 2026 marked an inflection point.

In May, Optum Rx announced a new pharmacy care model designed around transparency and predictability. The optional model offers plan sponsors a fee-based, per-member-per-month pricing option that is independent of manufacturer list prices and prescription volume.

The transparent model is paired with new digital tools that help consumers compare pricing and know the cost of their medication before they go to the pharmacy.

This new alternative represents a major change to longstanding practices of how pharmacies are reimbursed and how members receive their medicines. It also builds on existing Optum Rx transparency initiatives. These include plans to pass through 100% of negotiated drug rebates by 2028 and reduce prior authorizations for certain maintenance medications.

AI tools improve pharmacy care

Advanced technologies such as artificial intelligence seemed increasingly enmeshed in daily life. In 2026, these technologies began making a more pronounced impact on pharmacy care services.

Optum Assistant launched to make everyday pharmacy tasks easier. It adds conversational AI to the tools members already use to manage their prescription. This personalized support uses information from a member’s claims, benefit design, pharmacy network and formulary coverage. It can answer questions and identify ways to reduce out-of-pocket costs.

In a recent episode of the Pharmacy Insights Podcast, technology experts Ryan Perkins and Sarah Greenwell discussed these advances. They also explained how Optum Rx uses AI responsibly to simplify the member experience and expand client self-service options.

An innovative approach to menopause care

The need for solutions tailored to the unique health needs of women is vital to reducing overall health care costs for plan sponsors and improving workforce health.

This is especially true during menopause, when the risk of certain health conditions may increase as women progress through stages including perimenopause and post-menopause.

To address this need, in October we launched Optum Rx Menopause Care, a virtual program that makes menopause care easier to access. The program complements a woman’s existing care team. Menopause-trained clinicians provide support tailored to each woman’s stage of life.

The program features one-on-one coaching and personalized treatment options designed around each member’s unique health history, symptoms, and therapy preferences.

New GLP-1 drugs and indications

As with every year, new and expensive medications came to market in 2026. Most notably, drugs in the GLP-1 class, which are already a financial consideration for payers, entered a new phase in 2026. One of the most important developments of the year was the launch of two oral GLP-1 options for adults with obesity.

In early 2026, Novo Nordisk launched the recently FDA-approved oral version of Wegovy® for chronic weight management. It was soon followed by Foundayo™ an oral medication from Eli Lilly indicated for adults with obesity, or overweight with weight-related comorbidities. Unlike oral peptide-based GLP-1 therapies, Foundayo is a small-molecule drug without food or water restrictions. 

Importantly, the GLP-1 market continued to move beyond its traditional focus on type 2 diabetes and obesity. Drugs in the broader GLP-1/incretin class now have several expanded uses. These include cardiovascular risk reduction, obstructive sleep apnea in adults with obesity and chronic kidney disease.

GLP-1 drugs are just one of many drug classes financially impacting plan sponsors. To keep plan sponsors aware of noteworthy new treatments, our pipeline and drug surveillance team continuously monitors and evaluates drug development to share important upcoming approvals. To dive deeper, check out the latest new drug report from Optum Rx.

Related healthcare insights

Article

Top 5 ways Optum Rx is putting AI into action

See how we’re using AI to make pharmacy care faster, more personalized and proactive.

Report

A simpler GLP-1, plus big-market launches

This edition of Notable New Drugs includes another oral GLP-1, the first preventative treatment for COVID-19 and the most effective oral drug for plaque psoriasis.

Report

A busy end to 2026 for new drug approvals

Three anticipated approvals could reshape care in hepatitis B, stroke prevention and obesity. Explore the therapies poised to make an impact before year-end.